JP2013513659A - 腫瘍治療における有効なツールとしての腫瘍血管をターゲティングする新規なワクチン - Google Patents
腫瘍治療における有効なツールとしての腫瘍血管をターゲティングする新規なワクチン Download PDFInfo
- Publication number
- JP2013513659A JP2013513659A JP2012544429A JP2012544429A JP2013513659A JP 2013513659 A JP2013513659 A JP 2013513659A JP 2012544429 A JP2012544429 A JP 2012544429A JP 2012544429 A JP2012544429 A JP 2012544429A JP 2013513659 A JP2013513659 A JP 2013513659A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- edb
- tumor
- medical
- endosialin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 53
- 206010028980 Neoplasm Diseases 0.000 title abstract description 48
- 230000008685 targeting Effects 0.000 title description 10
- 210000004204 blood vessel Anatomy 0.000 title description 8
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 101000650590 Homo sapiens Roundabout homolog 4 Proteins 0.000 claims abstract description 39
- 102100027701 Roundabout homolog 4 Human genes 0.000 claims abstract description 39
- 102000007000 Tenascin Human genes 0.000 claims abstract description 20
- 108010008125 Tenascin Proteins 0.000 claims abstract description 20
- 102000004145 Annexin A1 Human genes 0.000 claims abstract description 19
- 108090000663 Annexin A1 Proteins 0.000 claims abstract description 19
- 102100038083 Endosialin Human genes 0.000 claims abstract description 19
- 101710144543 Endosialin Proteins 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims abstract description 13
- 239000002671 adjuvant Substances 0.000 claims abstract description 5
- 102100037354 Ectodysplasin-A Human genes 0.000 claims abstract 2
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 claims abstract 2
- 102100036505 Vesicle-associated membrane protein 8 Human genes 0.000 claims abstract 2
- 101710205049 Vesicle-associated membrane protein 8 Proteins 0.000 claims abstract 2
- 108020001507 fusion proteins Proteins 0.000 claims description 14
- 102000037865 fusion proteins Human genes 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102000014914 Carrier Proteins Human genes 0.000 claims description 8
- 108010078791 Carrier Proteins Proteins 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 241000282326 Felis catus Species 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims 6
- 241000282465 Canis Species 0.000 claims 4
- 241000282324 Felis Species 0.000 claims 4
- 241000009328 Perro Species 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 238000002255 vaccination Methods 0.000 description 13
- 230000033115 angiogenesis Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102400001047 Endostatin Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 101000852161 Homo sapiens Vesicle-associated membrane protein 8 Proteins 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 102400000731 Tumstatin Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 102000057137 human VAMP8 Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 description 2
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- -1 EDA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000037564 High-grade astrocytoma Diseases 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001027130 Mus musculus Fibronectin Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006481 angiogenic pathway Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108700002783 roundabout Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0901565-2 | 2009-12-15 | ||
| SE0901565A SE535982C2 (sv) | 2009-12-15 | 2009-12-15 | Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi |
| PCT/SE2010/000300 WO2011075035A1 (en) | 2009-12-15 | 2010-12-15 | A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013513659A true JP2013513659A (ja) | 2013-04-22 |
Family
ID=44167552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544429A Pending JP2013513659A (ja) | 2009-12-15 | 2010-12-15 | 腫瘍治療における有効なツールとしての腫瘍血管をターゲティングする新規なワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130122028A1 (de) |
| EP (1) | EP2512510A4 (de) |
| JP (1) | JP2013513659A (de) |
| CN (1) | CN102791290A (de) |
| AU (1) | AU2010332327A1 (de) |
| CA (1) | CA2783969A1 (de) |
| IN (1) | IN2012DN05163A (de) |
| RU (1) | RU2012124261A (de) |
| SE (1) | SE535982C2 (de) |
| WO (1) | WO2011075035A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104277102B (zh) * | 2014-06-27 | 2017-04-12 | 李光辉 | 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用 |
| CN107903307B (zh) * | 2017-10-17 | 2020-12-18 | 北京大学 | 一种高亲和力edb-fn蛋白靶向肽及其应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09505031A (ja) * | 1993-08-26 | 1997-05-20 | モーリトセン・アンド・エルスナー・エー／エス | 外来ｔ−細胞エピトープを補助として用いた、自己タンパク質に対する抗体応答の誘発 |
| JP2005509404A (ja) * | 2001-04-06 | 2005-04-14 | マンカインド コーポレイション | エピトープ配列 |
| JP2006524485A (ja) * | 2002-11-20 | 2006-11-02 | キャンサー・リサーチ・テクノロジー・リミテッド | 抗体、ポリペプチドおよびその使用 |
| US20060286074A1 (en) * | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
| JP2008526760A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用 |
| JP2008539188A (ja) * | 2005-04-29 | 2008-11-13 | バイオインヴェント インターナショナル アーベー | ポリペプチド、ワクチンおよびその使用 |
| JP2008543301A (ja) * | 2005-06-13 | 2008-12-04 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ | フィブロネクチンのｅｄａドメインの使用を基にした剤および方法 |
| JP2009518287A (ja) * | 2005-11-02 | 2009-05-07 | デューク ユニバーシティー | 同時の化学療法及び免疫療法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992017604A1 (en) * | 1991-03-26 | 1992-10-15 | Otsuka Pharmaceutical Factory, Inc. | Anti-eda monoclonal antibody |
| US5342757A (en) * | 1992-11-13 | 1994-08-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof |
| EP1752160A3 (de) * | 2001-04-06 | 2007-05-30 | Mannkind Corporation | Epitop-Sequenzen |
| TWI445525B (zh) * | 2004-06-02 | 2014-07-21 | Sidney Kimmel Cancer Ct | 用以偵測、成像和治療瘤新生或血管新生的血管標的物之用途 |
| ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
-
2009
- 2009-12-15 SE SE0901565A patent/SE535982C2/sv not_active IP Right Cessation
-
2010
- 2010-12-15 IN IN5163DEN2012 patent/IN2012DN05163A/en unknown
- 2010-12-15 EP EP10837964.5A patent/EP2512510A4/de not_active Withdrawn
- 2010-12-15 RU RU2012124261/10A patent/RU2012124261A/ru not_active Application Discontinuation
- 2010-12-15 AU AU2010332327A patent/AU2010332327A1/en not_active Abandoned
- 2010-12-15 CN CN2010800573573A patent/CN102791290A/zh active Pending
- 2010-12-15 JP JP2012544429A patent/JP2013513659A/ja active Pending
- 2010-12-15 US US13/516,385 patent/US20130122028A1/en not_active Abandoned
- 2010-12-15 WO PCT/SE2010/000300 patent/WO2011075035A1/en active Application Filing
- 2010-12-15 CA CA2783969A patent/CA2783969A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09505031A (ja) * | 1993-08-26 | 1997-05-20 | モーリトセン・アンド・エルスナー・エー／エス | 外来ｔ−細胞エピトープを補助として用いた、自己タンパク質に対する抗体応答の誘発 |
| JP2005509404A (ja) * | 2001-04-06 | 2005-04-14 | マンカインド コーポレイション | エピトープ配列 |
| JP2006524485A (ja) * | 2002-11-20 | 2006-11-02 | キャンサー・リサーチ・テクノロジー・リミテッド | 抗体、ポリペプチドおよびその使用 |
| JP2008526760A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用 |
| JP2008539188A (ja) * | 2005-04-29 | 2008-11-13 | バイオインヴェント インターナショナル アーベー | ポリペプチド、ワクチンおよびその使用 |
| US20060286074A1 (en) * | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
| JP2008543301A (ja) * | 2005-06-13 | 2008-12-04 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ | フィブロネクチンのｅｄａドメインの使用を基にした剤および方法 |
| JP2009518287A (ja) * | 2005-11-02 | 2009-05-07 | デューク ユニバーシティー | 同時の化学療法及び免疫療法 |
Also Published As
| Publication number | Publication date |
|---|---|
| SE535982C2 (sv) | 2013-03-19 |
| WO2011075035A1 (en) | 2011-06-23 |
| RU2012124261A (ru) | 2014-01-27 |
| SE0901565A1 (sv) | 2011-06-16 |
| AU2010332327A2 (en) | 2012-07-12 |
| EP2512510A4 (de) | 2014-02-26 |
| CN102791290A (zh) | 2012-11-21 |
| US20130122028A1 (en) | 2013-05-16 |
| EP2512510A1 (de) | 2012-10-24 |
| IN2012DN05163A (de) | 2015-10-23 |
| AU2010332327A1 (en) | 2012-07-05 |
| CA2783969A1 (en) | 2011-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sato et al. | Secretion of the baby hamster kidney 30-kDa galactose-binding lectin from polarized and nonpolarized cells: a pathway independent of the endoplasmic reticulum-Golgi complex | |
| JP5249282B2 (ja) | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 | |
| JP6941605B2 (ja) | 望まれない細胞増殖の除去又は破壊を必要とする疾患を治療するための組み合わせ組成物 | |
| JP2022048160A (ja) | Ｂｍｐ－ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用 | |
| CA2848368C (en) | Compositions and methods for brown fat induction and activity using fndc5 | |
| WO2010105573A1 (zh) | 抗血管新生融合蛋白 | |
| EP2547695B1 (de) | Tumorvakzinierung, die eine humorale Immunantwort gegen Selbstprotein CLDN18.2 beinhaltet | |
| AU2006319415B2 (en) | Multimeric complexes of antigens and an adjuvant | |
| WO1999033878A1 (fr) | Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales | |
| JP2020014468A (ja) | Ｈ因子活性を有する組換えタンパク質 | |
| JP2011502106A (ja) | マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法 | |
| JP2004513876A (ja) | 抗−腫瘍剤としてのｔａｃｉ | |
| JPH01502669A (ja) | 精製された血小板由来の成長因子及びその精製方法 | |
| Aurisicchio et al. | Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9 | |
| JP2013513659A (ja) | 腫瘍治療における有効なツールとしての腫瘍血管をターゲティングする新規なワクチン | |
| JP2021512966A (ja) | ワクチン組成物およびその使用 | |
| WO2014093387A1 (en) | Vegf receptor fusion proteins for veterinary use | |
| ZA200204987B (en) | Necleic acid vaccination. | |
| JP4570355B2 (ja) | 腫瘍およびその転移の治療のための医薬 | |
| Park et al. | Effect of a monoclonal antibody against human relaxin-2 on cancer cell growth inhibition | |
| CN105859837B (zh) | 胆固醇酯转运蛋白抗原肽和融合蛋白以及其组合物和应用 | |
| JP2008539188A (ja) | ポリペプチド、ワクチンおよびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131107 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150318 |